These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26111384)

  • 1. Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
    Kandela I; Jin HY; Owen K;
    Elife; 2015 Jun; 4():e07072. PubMed ID: 26111384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
    Aird F; Kandela I; Mantis C;
    Elife; 2017 Jan; 6():. PubMed ID: 28100400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia.
    Fung JJ; Kosaka A; Shan X; Danet-Desnoyers G; Gormally M; Owen K; ;
    Elife; 2015 Sep; 4():. PubMed ID: 26327698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
    Delmore JE; Issa GC; Lemieux ME; Rahl PB; Shi J; Jacobs HM; Kastritis E; Gilpatrick T; Paranal RM; Qi J; Chesi M; Schinzel AC; McKeown MR; Heffernan TP; Vakoc CR; Bergsagel PL; Ghobrial IM; Richardson PG; Young RA; Hahn WC; Anderson KC; Kung AL; Bradner JE; Mitsiades CS
    Cell; 2011 Sep; 146(6):904-17. PubMed ID: 21889194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer.
    Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
    Suzuki K; Yamamoto K; Arakawa Y; Yamada H; Aiba K; Kitagawa M
    Anticancer Drugs; 2016 Sep; 27(8):756-65. PubMed ID: 27276402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Registered Report: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Sharma V; Young L; Cavadas M; Owen K;
    Elife; 2016 Mar; 5():. PubMed ID: 26999821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Registered report: Biomechanical remodeling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis.
    Fiering S; Ang LH; Lacoste J; Smith TD; Griner E;
    Elife; 2015 Jul; 4():e04796. PubMed ID: 26179155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Registered report: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology.
    Khan I; Kerwin J; Owen K; Griner E; ;
    Elife; 2015 Sep; 4():. PubMed ID: 26335297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Registered report: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.
    Haven B; Heilig E; Donham C; Settles M; Vasilevsky N; Owen K; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26905833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Registered report: Interactions between cancer stem cells and their niche govern metastatic colonization.
    Incardona F; Doroudchi MM; Ismail N; Carreno A; Griner E; Anna Lim M;
    Elife; 2015 Jun; 4():e06938. PubMed ID: 26086719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Registered report: Wnt activity defines colon cancer stem cells and is regulated by the microenvironment.
    Evans J; Essex A; Xin H; Amitai N; Brinton L; Griner E; ;
    Elife; 2015 Aug; 4():. PubMed ID: 26287525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Registered report: Melanoma genome sequencing reveals frequent PREX2 mutations.
    Chroscinski D; Sampey D; Hewitt A;
    Elife; 2014 Dec; 3():. PubMed ID: 25490935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
    Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
    Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.
    Bhargava A; Anant M; Mack H; ;
    Elife; 2016 Feb; 5():. PubMed ID: 26885666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells.
    Vanden Heuvel JP; Bullenkamp J;
    Elife; 2016 Jun; 5():. PubMed ID: 27336789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21.
    Wang J; Wang Y; Mei H; Yin Z; Geng Y; Zhang T; Wu G; Lin Z
    Cancer Lett; 2017 Apr; 391():141-151. PubMed ID: 28143717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Registered report: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs.
    Phelps M; Coss C; Wang H; Cook M; ;
    Elife; 2016 Mar; 5():. PubMed ID: 26943900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
    Kandela I; Chou J; Chow K;
    Elife; 2015 May; 4():. PubMed ID: 27879198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.